Page: Aegis Foam Disc

Aegis is a hydrophilic foam disc impregnated with chlorhexidine gluconate (CHG) that supports clinical best practices and professional guidelines for reducing catheter-related bloodstream infections (CRBSI) and central line-associated bloodstream infections (CLABSI).2,3,6,7 It absorbs exudate and inhibits or kills microorganisms on the dressing’s surface.7

Experience the advantages of Aegis

Excellent absorbency

Absorbs up to 8x its weight in fluid with no distortion8

Fast kill rate

CHG begins killing bacteria within 2 hours7

Complete coverage

Provides 360° protection around the insertion site

Ongoing protection

Sustains progressive “kill” over 7 days7

Indications for use*

Aegis is a CHG-impregnated foam dressing that absorbs exudate and covers the peri-wound area of a wound caused by vascular and non-vascular percutaneous medical devices, such as:

AEG001S AEG014S AEG017S
Size 3/4″ disc (1.9 cm), 1.5 mm Hole 1″ (2.5 cm), 4 mm Hole 1″ disc (2.5 cm), 7 mm Hole
French size range <6Fr 6-12Fr 13-20Fr
CHG content 52.5 mg 92 mg 86.8 mg
Where to use
  • Arterial catheters
  • Extended dwell PIVs
  • Implanted venous ports
  • Midline catheters
  • Peripheral IV catheters
  • PICC lines
  • Pins
  • Epideral catheters
  • Central venous catheters
  • PICC lines
  • Dialysis catheters
  • Drains
  • Sheaths
  • LVADs
Pkg. 10/bx, 4 bx/cs 10/bx, 4 bx/cs 10/bx, 4 bx/cs

Fast kill rate

The CHG present in the dressing acts quickly, demonstrating a 4 log reduction in bacteria on the dressing’s surface within 2 hours.7

Excellent absorbency

The dressing’s two-layer foam absorbs up to eight times its weight in fluid with no distortion.8

Aegis product post fluid absorption

 

Leading competitor product post fluid absorption

References

  1. Hadaway LC. 5 Steps to Preventing Catheter-Related Bloodstream Infections. LPN2009. 2006;2(5):50-55. Available at: http://www.nursingcenter.com/ journalarticle?Article_ID=674810. Accessed December 21, 2016.
  2. Association for Professionals in Infection Control and Epidemiology. Guide to Preventing Central Line-Associated Bloodstream Infections. Washington, DC; APIC Implementation Guides, December 2015. Available at: http://www.apic.org/Professional-Practice/Implementationguides# Preventing. Accessed December 21, 2016.
  3. The Joint Commission. Preventing Central Line-Associated Bloodstream Infections: A Global Perspective. Oak Brook, IL: Joint Commission Resources, May 2012. Available at: https://www.jointcommission.org/assets/1/18/CLABSI_Monograph.pdf. Accessed December 21, 2016.
  4. Gahlot R, Nigam C, Kumar V, Yadav G, Anupurba S. Catheter-related bloodstream infections. International Journal of Critical Illness and Injury Science. 2014;4(2):162-167. Available at: https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC4093967/. Accessed June 6, 2017.
  5. Zimlichman E, Henderson D, Tamir O, et al. Health Care-Associated Infections: A Meta-Analysis of Costs and Financial Impact on the U.S. Health Care System. JAMA Intern Med. 2013;173(22):2039-2046. Available at: http://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1733452. Accessed November 18, 2016.
  6. Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011. O’Grady NP, Alexander M, Burns LA, et al. Centers for Disease Control and Prevention website. Available at: http://www.cdc.gov/hicpac/BSI/BSI-guidelines-2011.html. Accessed November 18, 2016.
  7. Marschall J, Mermel LA, Fakih M, Hadaway L, Kallen A, O’Grady NP, Pettis AM, Rupp ME, Sandora T, Maragakis LL, Yokoe DS. Strategies to Prevent Central Line-Associated Bloodstream Infections in Acute Care Hospitals: 2014 Update. Infection Control and Hospital Epidemiology, Vol. 35, No. 7 (July 2014), pp. 753-771. Available at http://www.jstor.org/stable/10.1086/676533. Accessed November 18, 2016.
  8. Data available upon request